Valuation: Jazz Pharmaceuticals plc

Market Cap 16.51B 14.15B 13.23B 12.1B 22.83B 1,581B 23.07B 157B 60.89B 794B 61.98B 60.63B 2,626B P/E 2026 *
17.6x
P/E 2027 * 15.8x
Enterprise Value 17.93B 15.37B 14.38B 13.14B 24.8B 1,717B 25.07B 170B 66.15B 862B 67.33B 65.87B 2,853B EV / Sales 2026 *
3.79x
EV / Sales 2027 * 3.25x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -
1 day-0.52%
1 week+1.64%
Current month-0.16%
1 month-0.56%
3 months+6.33%
6 months+45.23%
Current year+48.50%
1 week 245.76
Extreme 245.76
256.92
1 month 240.63
Extreme 240.631
265.04
Current year 156.95
Extreme 156.95
265.04
1 year 122.5
Extreme 122.5
265.04
3 years 95.49
Extreme 95.49
265.04
5 years 95.49
Extreme 95.49
265.04
10 years 86.88
Extreme 86.88
265.04
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-10
Director of Finance/CFO 62 2024-02-29
Chief Tech/Sci/R&D Officer 54 2023-07-31
Director TitleAgeSince
Chairman 62 2003-02-28
Director/Board Member 65 2012-01-17
Director/Board Member 66 2009-12-31
Date Insider Type Main position Quantity % Market Cap.
8/5/26 Free

Director

1,605 0.0026%
8/5/26 Free

Director

1,605 0.0026%
8/5/26 Free

Director

1,605 0.0026%
Change 5-day change 1-year change 3-year change Capi.($)
-0.52%+1.64%+102.62%+81.92% 16.51B
-0.58%+5.43%+79.40%+127.63% 1,119B
+1.22%+4.33%+53.42%+65.80% 651B
+0.35%+6.03%+27.88%+81.01% 468B
-1.38%+4.02%+42.52%+42.38% 374B
-0.52%+2.72%+25.21%+41.06% 302B
-1.06%+4.76%+2.00%+12.65% 259B
+0.54%+5.02%+52.68%+71.63% 238B
-0.53%+2.34%-18.53%-53.66% 208B
+0.25%+5.29%+28.13%+91.62% 181B
Average -0.24%+5.04%+39.53%+56.20% 381.64B
Weighted average by Cap. -0.17%+5.39%+46.17%+73.09%

Financials

2026 *2027 *
Net sales 4.73B 4.05B 3.79B 3.46B 6.54B 452B 6.61B 44.83B 17.43B 227B 17.74B 17.36B 752B 4.99B 4.27B 4B 3.65B 6.9B 477B 6.97B 47.3B 18.39B 240B 18.72B 18.32B 793B
Net income 993M 851M 797M 728M 1.37B 95.13B 1.39B 9.43B 3.66B 47.77B 3.73B 3.65B 158B 1.14B 974M 911M 833M 1.57B 109B 1.59B 10.79B 4.19B 54.66B 4.27B 4.18B 181B
Net Debt 1.42B 1.22B 1.14B 1.04B 1.97B 136B 1.99B 13.52B 5.26B 68.51B 5.35B 5.23B 227B -303M -260M -243M -222M -420M -29.05B -424M -2.88B -1.12B -14.59B -1.14B -1.11B -48.26B
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Employees
2,890
Date Price Change Volume
26-08-24 US$252.45 -0.72% 72,111
26-08-21 US$254.28 +2.24% 516,753
26-08-20 US$248.70 -1.37% 439,915
26-08-19 US$252.16 -0.36% 549,516
26-08-18 US$253.07 +1.90% 459,255
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
254.28USD
Average target price
281.35USD
Spread / Average Target
+10.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JAZZ Stock